HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Michel Carrier Raymond Cartier Yves Leclerc Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carrier, M. Articles by Pelletier, L. C. Search for Related Content PubMed PubMed Citation Articles by Carrier, M. Articles by Pelletier, L. C.

Ann Thorac Surg 1994;57:353-356
© 1994 The Society of Thoracic Surgeons

---

Articles

Cholesterol-lowering intervention and coronary artery disease after cardiac transplantation

Departments of Surgery and Medicine, Montreal Heart Institute, Montreal, Quebec, Canada

Accepted for publication March 23, 1993.

^_* Address reprint request to Dr Carrier, Research Department, Montre Heart Institute, 3000 Belanger St E, Montreal, Que HIT 1C8, Canada.

Allograft coronary artery disease is a major threal to long-term survival after cardiac transplantation. It has been suggested that hyperlipidemia plays a major role in allograft coronary disease. The objective of the present study was to evaluate the effect of a lipid-lowering intervention with diet and drug therapy after cardiac transplantation. Forty-six patients who underwent transplantation between 1988 and 1991 and who were treated with the American Heart Association phase 1 diet and an HMG coenzyme A reductase inhibitor (lovastatin or simvaslatin) when low-density lipoprotein cholesterol levels were higher than 3 ^l mmol/L were compared with 35 untreated patients having transplantation between 1983 and 1988. Annual coronary angiograms were obtained in both groups. Cholesterol, triglyceride, and low-density lipoprotein levels were significantly lower in the treated group. Actuarial survival and event-free survival (survival free from allograft coronary artery disease) were similar in both groups. Low-density lipoprotein levels lower than 3 mmol/L at the last follow-up had a positive effect on event-tree survival. The cholesterol-lowering intervention was not effective in decreasing the prevalence of allograft coronary artery disease. This study suggests that more aggressive measures to lower low-density lipoprotein levels may be necessary to significantly affect allograft disease. Clinical trials should be developed to address this hypothesis.

This article has been cited by other articles:

				E. R. Edelman and H. D. Danenberg Rapamycin for Cardiac Transplant Rejection and Vasculopathy: One Stone, Two Birds? Circulation, July 8, 2003; 108(1): 6 - 8. [Full Text] [PDF]

				K. Wenke, B. Meiser, J. Thiery, D. Nagel, W. von Scheidt, K. Krobot, G. Steinbeck, D. Seidel, and B. Reichart Simvastatin Initiated Early After Heart Transplantation: 8-Year Prospective Experience Circulation, January 7, 2003; 107(1): 93 - 97. [Abstract] [Full Text] [PDF]

				K. Wenke, B. Meiser, J. Thiery, D. Nagel, W. von Scheidt, G. Steinbeck, D. Seidel, and B. Reichart Simvastatin Reduces Graft Vessel Disease and Mortality After Heart Transplantation : A Four-Year Randomized Trial Circulation, September 2, 1997; 96(5): 1398 - 1402. [Abstract] [Full Text]